TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
WST

West Pharmaceutical Services Inc

Healthcare · Medical Instruments & Supplies · listed since 1978

366.60$ +1.3% vs. previous close Closing price · As of: Sep 17, 2026
🔔 Watch stock
Add to watchlist

Assessment

Our Rating

A journalistic assessment by our editorial team at the time of the deep dive — it rates the company, not the entry point. Not investment advice and not a solicitation to buy or sell.

Open questions

The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.

Why this colour

Whoever buys today is betting that the GLP-1 surge of the first quarter of 2026 is the start of a multi-year run, and justifies 47 times earnings with it — comforted by a balance sheet and dividend streak that guard the downside. Whoever waits checks three lines in every quarterly report (10-Q): revenue growth (does it stay double-digit?), the largest customer's share (does it keep climbing toward 20 percent?) and any news on renewing the Daikyo licenses before 2027. The next quarterly numbers arrive as soon as July 23, 2026 — an early reading. As long as price and proof sit this far apart, the stock is a watch-list position with clear checkpoints. The decision is yours.

What the thesis turns on

Assessment: Opportunities & Risks

West Pharmaceutical is the rare case in which the noble title is accurate and can still mislead: 33 SEC-documented consecutive dividend increases, a fortress balance sheet and a tollbooth position in injectable medicine — but a yield around 0.3 percent, a share price at 47 times earnings, and a growth story that hangs on the weight-loss pen, one 15.8 percent customer and Daikyo licenses expiring in 2027. Whoever buys here is not buying a dividend stock but a richly priced quality-growth bet. Not investment advice.

Business model & market position

Consumables with a regulatory moat: elastomer components are baked into customers' drug approvals, and every supplier switch costs data and regulator visits — a tollbooth of injectable medicine with $3,074.1 million in 2025 revenue and a 16 percent net margin (annual report 10-K 2025).

Dividend history & safety

33 consecutive increases (SEC-documented chain: 21st increase 2013, 28th increase 2020, $0.22 per quarter since Q4 2025) at only about 13 percent payout — the streak is exceptionally well covered; the roughly 0.3 percent yield, however, makes the stock no income play (data as of mid-July 2026).

Balance sheet & capital returns

$791.3 million in cash (12/31/2025), equity ratio around 73 percent, net interest paid $0.3 million; buybacks of $1.43 billion since early 2023, a new $1.0 billion program since February 2026, Q1 2026 purchases at ~$244 per share (10-K 2025, 10-Q 03/31/2026).

Growth & the GLP-1 cycle

A strong comeback in Q1 2026 (+21.0 percent revenue, diluted EPS $1.92 after $1.23), driven by high-value components and GLP-1 self-injection systems — but only one quarter after two hangover years: 2025 net income ($493.7 million) still sat below 2023 ($593.4 million), and customer inventory cycles left their mark in 2024.

Concentration risks (big customer & Daikyo)

The largest (unnamed) customer jumped from 12.3 to 15.8 percent of revenue within a year ($485.9 million), the top ten account for 47.6 percent; at the same time the Daikyo licenses for FluroTec, B2 and Crystal Zenith expire in 2027, and the risk factors name oral GLP-1s as a concrete threat to the injection business (10-K 2025).

Valuation

Roughly 47 times trailing earnings, 7.5 times revenue and a good 50 times free cash flow (data as of mid-July 2026) — the multiple of a structural growth stock, paid after a single quarter of renewed acceleration; the non-affiliate market value stood at $15.7 billion as recently as 06/30/2025 per the 10-K.

Worth Noting

WST entered the research list as rank 4 of the in-house dividend-aristocrats scanner (U.S. selection, as of July 18, 2026); 19 further scanners flagged it at the same time — from quality growth and the Buffett criteria to momentum signals (Stage 2, Power Trend).

The 33-year streak is reconstructed from SEC sources: 8-K press releases of 08/01/2013 (21st increase) and 10/28/2020 (28th increase) plus the gaplessly rising, split-adjusted XBRL dividend series 2011–2025 ($0.35 → $0.86). Scanner metrics (P/E, P/S, Piotroski, Altman-Z) use trailing twelve-month figures.

Market-value figure (~$24 billion) from the feed as of mid-July 2026, sanity-checked against 72,021,491 shares outstanding per the annual report 10-K 2025 (as of 01/29/2026); analyses are evergreen, daily prices are not a buy argument.

Read the Full Deep Dive West Pharmaceutical Stock: 33 Straight Dividend Increases — and Still Only a 0.3 Percent Yield West Pharmaceutical makes the rubber stoppers and seals without which hardly any injectable drug reaches the market — the weight-loss pens run on components from Exton, Pennsylvania, too. Our in-house stock scanner ranks the stock number 4 among dividend aristocrats (U.S. selection, as of July 18, 2026): the quarterly dividend has risen for 33 consecutive years. We read the annual reports (10-K), the quarterly report (10-Q) as of March 31, 2026, and the dividend announcements back to 2013: a payout ratio of just 13 percent, an unnamed customer worth 15.8 percent of revenue, key licenses expiring in 2027 — and a share price at 47 times earnings. Not investment advice — just the question of whether a noble title is an investment case. Read the analysis →

Stock Watch

This analysis is as of August 26, 2026. Stock Watch will tell you what's changed at WST since then.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Price history

Chart

Interactive price chart (TradingView).

52-week range: 231.00 $ to 366.60 $ · Last price: 366.60 $ (As of: September 17, 2026)

Key figures

Key figures at a glance

Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.

Basics

Market Cap ?The value of the entire company on the market: share price times total shares outstanding. 25.4$B
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 70m
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 99.3%
Beta ?Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market. 1.1

Performance

Perf. 1M ?Price performance over the last month. 10.20%
Perf. 3M ?Price performance over the last 3 months. 45.90%
Perf. 6M ?Price performance over the last 6 months. 28.40%
YTD Performance (%) ?Price performance since the start of the year (Year to Date). 22.50%
52-Week-High Distance ?How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high. -1.6%
Perf. 1Y ?Price performance over the last 12 months. 43.29%
Perf. 3Y ?Price performance over the last 3 years. -6.20%
Perf. 5Y ?Price performance over the last 5 years. -17.20%
Perf. 10Y ?Price performance over the last 10 years. 367.14%
Perf. Since Inception ?Price performance since the first available trading day (03/17/1980) — with a complete history, that is since the IPO. 118,579.18%

Technical Indicators

MA 38 Days ?Moving average of the last 38 trading days: the smoothed price path. A price above it signals short-term strength. 347.20$
MA 50 Days ?Moving average of the last 50 trading days — the most widely watched medium-term trend line. 349.10$
MA 200 Days ?Moving average of the last 200 trading days — the dividing line between a long-term uptrend and downtrend. 297.00$
RSI (14) ?Relative Strength Index over 14 days, scale 0 to 100: above 70 counts as overbought, below 30 as oversold. A hint on timing, not a verdict on the company. 66.6
Volatility 30 Days ?Price swings over the last 30 trading days, annualized. The higher the value, the more the price fluctuates. 19.9%
Volatility 250 Days ?Price swings over the last 250 trading days (roughly one market year), annualized. 33.3%

Calculated from the price history · as of 09/18/2026

Valuation

P/E ?Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E. 50.2
Forward P/E ?P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future. 36.5
PEG ?P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey. 2.8
P/B ?Price-to-book ratio: market value relative to book equity. 8.9
P/S ?Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable. 7.6
EV/EBITDA ?Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero. 28.3
Price/FCF ?Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up. 58.1

Profitability

Gross Margin ?Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power. 36.8%
EBIT Margin ?EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes. 21.7%
Net Margin ?Net margin: what's left of sales as profit after ALL costs, interest, and taxes. 17.0%
Return on Equity ?Return on equity: how much profit does the company generate per year on shareholders' equity? 19.1%
Return on Assets ?Return on assets: how much profit the company generates from its total assets (equity and debt combined). 11.4%

Balance Sheet & Safety

Equity Ratio ?Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet. 72.8%
Debt/Equity ?Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity. 0.1
Altman Z″ ?Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks. fortress balance sheet 12.54
Piotroski ?Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag. 7 out of 9

Growth

Sales Growth Last Quarter ?Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY). 21.00%
EPS Growth Last Quarter ?Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY). 56.10%
Sales Growth (Year) ?Sales growth in the last fiscal year versus the year before. 6.26%
Forward Sales Growth ?Sales growth analysts expect over the next 12 months — an estimate, not a guarantee. 6.19%
Forward EPS Growth ?Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee. 11.00%

Dividend

Dividend Yield ?Annual dividend divided by the current price: what percentage of your investment comes back as a payout each year. 0.25%
Dividend Per Share (TTM) ?Sum of dividends paid per share over the last 12 months. 0.88$
Payout Ratio ?Share of profit paid out as dividends. Over 100% means the company is paying out more than it earns — not sustainable long-term. 10.4%
Years Without a Cut ?How many years in a row the dividend hasn't been cut — a measure of reliability. 29Years
Increase Streak ?How many years in a row the dividend has been raised — the gold standard for dividend payers. 29Years

Quality & Screener

Stage ?Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line. 2
RS Rating ?Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks. 80
EPS Rating ?Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth. 79
Fundamental Rating ?Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below. B (69 out of 100)

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Comparison

Industry comparison

The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.

Industry: Medical Instruments & Supplies

Industry comparison
Company Market cap ($B) P/E EV/EBITDA Gross Margin % EBIT Margin % Sales Growth (Year) % Perf. 1Y %
West Pharmaceutical Services Inc WST 25.4 50.2 28.3 36.8 21.7 6.3 43.3
Intuitive Surgical Inc ISRG 135.7 47.7 29.5 66.7 30.9 20.5 -11.6
Becton Dickinson and Company BDX 50.0 33.0 13.4 46.9 14.7 8.2 27.3
Medline Inc. MDLN 43.2 26.7 14.0 25.1 5.4 11.5 –
ResMed Inc RMD 32.7 22.2 14.6 61.6 35.3 9.8 -15.4
Solventum Corp. SOLV 15.1 10.8 8.2 54.8 5.6 0.9 18.2
Baxter International Inc BAX 11.6 – 26.1 34.1 6.0 5.7 -0.6
Align Technology Inc ALGN 11.1 25.6 10.9 70.7 16.6 0.9 15.7
Avantor Inc AVTR 10.9 – 122.5 31.8 6.3 -3.4 27.9
Median of companies shown 25.4 26.7 14.6 46.9 14.7 6.3 16.9

Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →

Fiscal years

Annual Figures

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

Revenue, operating income and net income per fiscal year $M

Revenue Operating income Net income

2016 · Revenue: 1,509 $M 2016 · Operating income: 197 $M 2016 · Net income: 144 $M 2017 · Revenue: 1,599 $M 2017 · Operating income: 229 $M 2017 · Net income: 151 $M 2018 · Revenue: 1,718 $M 2018 · Operating income: 255 $M 2018 · Net income: 207 $M 2019 · Revenue: 1,844 $M 2019 · Operating income: 297 $M 2019 · Net income: 242 $M 2020 · Revenue: 2,147 $M 2020 · Operating income: 419 $M 2020 · Net income: 346 $M 2021 · Revenue: 2,831 $M 2021 · Operating income: 759 $M 2021 · Net income: 662 $M 2022 · Revenue: 2,886 $M 2022 · Operating income: 764 $M 2022 · Net income: 586 $M 2023 · Revenue: 2,951 $M 2023 · Operating income: 711 $M 2023 · Net income: 593 $M 2024 · Revenue: 2,893 $M 2024 · Operating income: 595 $M 2024 · Net income: 493 $M 2025 · Revenue: 3,074 $M 2025 · Operating income: 617 $M 2025 · Net income: 494 $M
2016201720182019202020212022202320242025
Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2016 1,509 197 144 1.91 219 1,118 1,717
2017 1,599 229 151 1.99 263 1,666 1,863
2018 1,718 255 207 2.74 289 1,396 1,592
2019 1,844 297 242 3.21 367 1,573 2,341
2020 2,147 419 346 4.57 473 1,855 2,794
2021 2,831 759 662 8.67 584 2,335 3,314
2022 2,886 764 586 7.73 724 2,685 3,617
2023 2,951 711 593 7.88 777 2,881 3,830
2024 2,893 595 493 6.69 653 2,682 3,643
2025 3,074 617 494 6.79 755 3,176 4,270

Quarters

Quarterly Figures

Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 748.5 $M Q4 2025: Q1 · 698.2 $M Q1 2025: Q2 · 766.2 $M Q2 2025: Q3 · 804.3 $M Q3 2025: Q4 · 805.0 $M Q4 2026: Q1 · 844.9 $M Q1 2026: Q2 · 872.3 $M Q2

Source: fundamental data

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 1.77 -3.40 749 2.20 17.40 190 85
2025: Q1 1.23 -20.70 698 0.40 12.90 129 58
2025: Q2 1.81 19.90 766 9.10 17.20 177 102
2025: Q3 1.93 3.90 804 7.70 17.40 197 134
2025: Q4 1.82 2.90 805 7.50 16.40 251 175
2026: Q1 1.92 55.80 845 21.00 16.40 90 47
2026: Q2 2.15 18.80 872 13.80 17.70 124 81

What Do These Terms Mean?

EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Compare with other stocks →

Screening

Appears in These Scanners

This stock currently matches 22 of our scanner strategies — each hit links to the scanner.

Backtested Scanners

Growth

Quality & Balance Sheet

Aktien.Guide

Breakout & Setup

Momentum & Trend

Research

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Outlook

Analysts & Price Target

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Consensus Strong Sell 1 = Strong buy … 5 = Strong sell
Analyst Ratings 13
Price Target (average) 405.38$
Distance to price 10.6% The price target sits 10.6% above the current price.

Distribution of Recommendations

Strong Buy 10
Buy 2
Hold 1
Sell 0
Strong Sell 0

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 8.96 8.83 – 9.05 3,374 22.9% 17
12/31/2027 9.98 9.71 – 10.67 3,586 11.3% 17

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Valuation

What is priced in?

Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.

Today’s market value implies roughly 22.3% growth in free cash flow per year over ten years (assumptions: discount rate 10.0%, terminal growth 2.5%).

What is priced in?
Free cash flow (last twelve months) $436.9M
Market cap $25.39B
Free cash flow in year ten $3.26B
Terminal value as a share of market value 67.8%

For comparison: over the past five years free cash flow grew by 9.5% per year.

It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.

A simplified model calculation — not a forecast and not a recommendation.

AI classification

AI Rating

Neutral

Geprüft am 18.07.2026 gegen den Geschäftsbericht (10-K) 2025 (eingereicht 17.02.2026), den 10-K 2024 (18.02.2025) und die vier jüngsten Quartalsberichte (10-Q, zuletzt zum 31.03.2026): In keinem der sechs ausgewerteten SEC-Filings von West Pharmaceutical findet sich auch nur eine Erwähnung von „artificial intelligence“, „machine learning“, „generative“, „LLM“ oder „AI“ — der Volltext-Scan (inklusive Schreibvarianten) liefert null Treffer. Das Geschäft (Elastomer-Stopfen, Dichtungen, Injektionssysteme für injizierbare Medikamente) wird in den Berichten ohne jeden KI-Bezug beschrieben; weder KI-Umsatzquelle noch operativer KI-Einsatz noch ein konkretes KI-Geschäftsrisiko fürs eigene Modell sind dokumentiert. Ergänzend gesichtet: Die Proxy-Erklärung (DEF 14A, 12.03.2026) erwähnt „artificial intelligence“ nur als Themenpunkt der überarbeiteten Verhaltenskodizes (Code of Conduct) — Governance-Boilerplate ohne Geschäftsmodell-Bezug, nach dem Kriterienkatalog kein Beleg. Dokumentierter Negativ-Befund → neutral.

View the full file — quotes, sources, reviewed filings

Filings Reviewed: 10-Q 2026-04-23 · 10-Q 2025-10-23 · 10-Q 2025-07-24 · 10-Q 2025-04-24 · 10-K 2026-02-17 · 10-K 2025-02-18

Rated on July 18, 2026 · How the Rating Is Built

Growth

Growth Score

Ten checks against the annual reports — each one passed counts a point.

5 of 10 Solid growth
  • Revenue grows by more than 15% a year over three years 2.1%
  • More than 10% revenue growth is expected for the coming year 6.2%
  • Share count grows by less than 3% a year -1.4%
  • Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 21.5%
  • Gross margin at 40% or higher and without meaningful erosion 35.9%
  • Goodwill from acquisitions does not grow faster than revenue 2.6%
  • Net debt below twice EBITDA 375 m net cash
  • Operating cash flow covers the profits of the last three years 605 m
  • Return on capital at 15% or higher, or up versus two years ago 17.1%
  • Insiders hold at least 10% or are net buyers 0.6%

A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail

Quality check

AAQS

10/10 Quality stock

The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).

  • Sales growth 10Y > 5% 8.2%
  • Exp. sales growth 3Y > 5% 8.0%
  • EBIT growth 10Y > 5% 13.5%
  • Exp. EBIT growth 3Y > 5% 21.2%
  • Net debt < 4x EBIT -0.6x
  • EBIT positive, 10Y straight 10
  • Max. EBIT decline < 50% 22.1%
  • Return on equity > 15% 16.1%
  • ROCE > 15% 17.1%
  • Expected return > 10% 23.4%

View stocks with the full AAQS score · Read the methodology at AlleAktien

Source: fundamental data

Insiders

Insider Transactions

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

Insider Transactions
Date Person Role Type Shares Price Value
Sep 15, 2026 Favorite Annette F Sr. VP & Chief HR Officer Sell 2,524 365.00 921,260
Sep 15, 2026 Favorite Annette F Sr. VP & Chief HR Officer Other 2,524 89.64 226,251
Sep 14, 2026 Favorite Annette F Sr. VP & Chief HR Officer Sell 2,500 355.00 887,500
Sep 14, 2026 Favorite Annette F Sr. VP & Chief HR Officer Other 2,500 89.64 224,100
Sep 11, 2026 Favorite Annette F Sr. VP & Chief HR Officer Sell 2,500 345.00 862,500
Sep 11, 2026 Favorite Annette F Sr. VP & Chief HR Officer Other 2,500 89.64 224,100
Sep 8, 2026 Favorite Annette F Sr. VP & Chief HR Officer Sell 2,500 340.81 852,025
Sep 8, 2026 Favorite Annette F Sr. VP & Chief HR Officer Other 2,500 89.64 224,100
Sep 8, 2026 Favorite Annette F Sr. VP & Chief HR Officer Sell 2,818 340.81 960,403
Sep 8, 2026 Favorite Annette F Sr. VP & Chief HR Officer Other 2,818 83.47 235,218

View all insider transactions →

The company

About the Company

West Pharmaceutical Services, Inc. entwickelt, fertigt und verkauft Behälter- und Verabreichungssysteme für injizierbare Arzneimittel und Gesundheitsprodukte in Nord- und Südamerika, Europa, dem Nahen Osten, Afrika und dem asiatisch-pazifischen Raum.

Employees
10,800
Headquarters
Exton, PA
Address
530 Herman O. West Drive, 19341-1147 Exton, United States
Phone
610 594 2900
IPO Date
01/13/1978
ISIN
US9553061055
Stock Split
2:1 on 09/27/2013
Stock Split
2:1 on 09/29/2004
Stock Split
2:1 on 06/02/1987

Management

Management
Name Title Birth Year
Robert W. McMahon C.M.A. Senior VP & CFO 1969
Annette F. Favorite Chief HR Officer & Senior VP 1965
Shane A. Campbell SVP & Chief Proprietary Segment Officer 1980
Michel Lagarde President, CEO & Director 1975
Chad R. Winters VP of Finance & Chief Accounting Officer 1979
Devesh Mathur Senior VP & CTO –
John P. Sweeney C.F.A. Vice President of Investor Relations –
Norman D. Finch Jr. Senior VP, General Counsel & Corporate Secretary 1965
Michele Polinsky Vice President of Global Communications –
Rudy J. Poussot Senior Vice President of Strategy & Corporate Development 1970

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Filings

Company Filings (8-K)

An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).

  • 07/23/2026 WEST PHARMACEUTICAL SERVICES INC (WST): Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
  • 07/14/2026 WEST PHARMACEUTICAL SERVICES INC (WST): Entry into a Material Definitive Agreement; Financial Statements and Exhibits SEC ↗

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?